THE BEST SIDE OF GLIBORNURIDE

All enrolled individuals who acquired at the least a single dose of zosuquidar or placebo during induction have been monitored with the event of adverse situations (439 individuals, 219 on zosuquidar and 210 on placebo). The most typical adverse gatherings were relevant to the duration of prolonged and sizeable myelosuppression as is expected with